Session » Immunological Complications of Medical Therapy Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0752

A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis

9:00AM-10:30AM: Abstract Number: 0773

Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease

9:00AM-10:30AM: Abstract Number: 0767

Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies

9:00AM-10:30AM: Abstract Number: 0766

CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients

9:00AM-10:30AM: Abstract Number: 0776

Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey

9:00AM-10:30AM: Abstract Number: 0769

Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial

9:00AM-10:30AM: Abstract Number: 0774

HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases

9:00AM-10:30AM: Abstract Number: 0753

Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study

9:00AM-10:30AM: Abstract Number: 0761

Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group

9:00AM-10:30AM: Abstract Number: 0777

Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study

9:00AM-10:30AM: Abstract Number: 0770

Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies

9:00AM-10:30AM: Abstract Number: 0755

Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients

9:00AM-10:30AM: Abstract Number: 0763

Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

9:00AM-10:30AM: Abstract Number: 0759

Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study

9:00AM-10:30AM: Abstract Number: 0772

New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review

9:00AM-10:30AM: Abstract Number: 0764

No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors

9:00AM-10:30AM: Abstract Number: 0754

Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure

9:00AM-10:30AM: Abstract Number: 0760

Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors

9:00AM-10:30AM: Abstract Number: 0768

Reevaluating Clinical Outcomes of Patients on Combination Biologics

9:00AM-10:30AM: Abstract Number: 0758

Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study

9:00AM-10:30AM: Abstract Number: 0756

Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions

9:00AM-10:30AM: Abstract Number: 0762

Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders

9:00AM-10:30AM: Abstract Number: 0757

Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases

9:00AM-10:30AM: Abstract Number: 0775

The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment

9:00AM-10:30AM: Abstract Number: 0765

The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)

9:00AM-10:30AM: Abstract Number: 0771

The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study

9:00AM-10:30AM: Abstract Number: 0778

TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases

« View all sessions from this meeting